SC 13G/A

Names of Reporting Persons

BB Biotech AG

Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ☒ (b) ☐

SEC Use Only

Citizenship or Place of Organization

Switzerland

SC 13G/A 1 d134370dsc13ga.htm SC 13G/A SC 13G/A

United States

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2)*

KEZAR LIFE SCIENCES, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

49372L100

(CUSIP Number)

December 31, 2020

(Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 49372L100

2 of 6

CUSIP No. 49372L100

3 of 6

Item 1

1(a)

Name of Issuer: Kezar Life Sciences, Inc.

1(b)

Address of Issuer’s Principal Executive Offices:

4000 Shoreline Court, Suite 300, South San Francisco, CA, 94080

Item 2

2(a)

Name of Person Filing: BB Biotech AG (“BB Biotech”) on behalf of its wholly-owned subsidiary, Biotech Growth N.V. (“Biotech Growth”)

2(b)

Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

2(c)

Citizenship: BB Biotech AG: Switzerland

Biotech Growth N.V.: Curacao

2(d)

Title of Class of Securities Common Stock, $0.001 par value

2(e)

CUSIP Number 49372L100

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a)

Amount beneficially owned: 4,533,148

(b)

Percent of class: 9.8%

(c)

Number of shares as to which the person has:

(i)

Sole power to vote or to direct the vote 0

(ii)

Shared power to vote or to direct the vote 4,533,148

(iii)

Sole power to dispose or to direct the disposition of 0

(iv)

Shared power to dispose or to direct the disposition of 4,533,148

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Growth, Biotech Growth is a wholly-owned subsidiary of BB Biotech.

4 of 6

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG


Date: February 11, 2021	By:	/s/ Martin Gubler
		Signatory Authority

	Name:	Martin Gubler

	Title:	Signatory Authority

Date: February 11, 2021	By:	/s/ Ivo Betschart
		Signatory Authority

	Name:	Ivo Betschart

	Title:	Signatory Authority

Biotech Growth N.V.

Date: February 11, 2021	By:	/s/ Jan Bootsma
		Signatory Authority

	Name:	Jan Bootsma

	Title:	Signatory Authority

Date: February 11, 2021	By:	/s/ Hugo van Neutegem
		Signatory Authority

	Name:	Hugo van Neutegem

	Title:	Signatory Authority

5 of 6

Exhibit Index

Exhibit A: Agreement by and between BB Biotech AG and Biotech Growth N.V. with respect to the filing of this disclosure statement.*

*	Previously filed as an exhibit to BB Biotech AG and Biotech Growth N.V.’s Schedule 13G filed with the Securities and Exchange Commission on January 31, 2019.

6 of 6

SEC Form SC 13G/A filed